EGFR and large cell neuroendocrine carcinoma: A case report introduced a patient with metastatic LCNEC harboring EGFR-activating mutation who received the therapy with erlotinib and did not respond to erlotinib at its usual dose, after which he died with a survival of 4 months [66].